Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of NZ725567ApublicationCriticalpatent/NZ725567A/en
Disclosed is the use of an antibody that binds R-spondin 2 (RSPO2) and/or R-spondin 3 (RSPO3) for the preparation of a medicament for treatment of colorectal cancer, wherein the cancer or the cancer cell comprises an RSPO2 and/or RSPO3 translocation.
NZ72556713A2012-02-112013-02-11R-spondin translocations and methods using the same
NZ725567A
(en)
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer